[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"corneal-dystrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:corneal-dystrophy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,91,116,139],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100553863","national-ophthalmic-genotyping-and-phenotyping-network-eyegene-registered-trademark-stage-3---expansion-of-dna-and-data-repositories-for-rare-inherited-ophthalmic-diseases-100553863",false,"NCT06491615","National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases","National Ophthalmic Genotyping and Phenotyping Network, Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\nThe participant must present with characteristics consistent with one of the following diagnoses:\n\n* Aniridia\n* Best disease\n* Blue-cone monochromacy\n* Corneal dystrophy\n* Other hypopigmentation disorder affecting vision (e.g., Oculocutaneous and ocular albinism, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome)\n\nOR\n\nThe participant must be a direct, close relative of an affected participant.\n\nOR\n\nA participant who also participated in the eyeGENE Stage 1 protocol who may benefit from further genetic testing.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Those with impaired decision-making capability who do not have a legally-authorized representative.\n* Those unable to provide a saliva sample OR have any disease or condition that makes it unsafe for a subject to provide a suitable blood sample of at least 5 mL to yield more than 50 micrograms of DNA.\n\nAn individual who meets any of the following criteria will be excluded from participation in the optional retinal imaging:\n\n* Those with a history of epilepsy.\n* Children under the age of 18.","ALL","1 Day","120 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","Background:\n\nThe eyeGENE (Registered Trademark) program is a research resource for inherited eye conditions which includes genotypic and phenotypic data, imaging, and a corresponding biobank of DNA samples from people with a variety of eye diseases. Since 2007 this registry has been helping researchers learn more about the genetic sources for many inherited eye diseases. These findings helped them create better treatments. Now researchers want to expand eyeGENE (Registered Trademark) to include more people for certain eye diseases.\n\nObjective: To collect information and DNA samples for the study of eye diseases.\n\n* Primary objective\n\n  --To expand the current eyeGENE (Registered Trademark) data repository with targeted participant accrual\n* Secondary objectives\n\n  * To enhance recruitment for clinical trials and investigations in inherited eye diseases\n\n    * To establish genotype-phenotype correlations for rare eye diseases\n\nEligibility:\n\nPeople of any age with certain eye diseases. These can include aniridia; Best disease; blue-cone monochromacy; corneal dystrophy; and disorders of pigmentation, such as albinism. Relatives unaffected by the eye disease of interest may also be needed.\n\nDesign:\n\nResearchers will select participants based on their diagnosis. The data may include images and test results from eye exams.\n\nParticipants will provide a sample of saliva. They will receive a kit with written instructions. They will spit in a tube and mail it to the NIH.\n\nParticipants may be asked to provide a blood sample. The blood may be drawn at the NIH or at a local clinic.\n\nThe eyeGENE (Registered Trademark) repository will offer researchers data about the participants eye conditions. The data may include pictures of their eyes, results of the genetic testing, and history of other diseases. Researchers will be able to see data such as age and gender, but they will not see names, dates of birth, or contact information.",[25,26,27,28,29,30,31],"Inherited Ophthalmic Diseases","Hypopigmentation Disorder","Corneal Dystrophy","Blue-cone Monochromacy","Best Disease","Aniridia","Albinism",[33,34,35],"eyeGENE","Genetics","Inherited","RECRUITING","2026-06-06",{"date":39,"type":40},"2026-06-09","ACTUAL",{"date":42,"type":40},"2024-07-12",{"date":44,"type":21},"2054-06-27",{"name":46,"class":47},"National Eye Institute (NEI)","NIH",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100372409","high-resolution-high-speed-multimodal-ophthalmic-imaging-100372409","NCT04129021","High Resolution, High-speed Multimodal Ophthalmic Imaging","High Resolution and High Speed Multimodal Ophthalmic Imaging","IMA-MODE","Inclusion Criteria:\n\n* People over 18\n* Patient with a pathology affecting the eye or healthy volunteer\n* Participant who signed the consent\n* Beneficiaries of the health insurance\n\nExclusion Criteria:\n\n* Patients with a history of photosensitivity.\n* Patients who have just received a photodynamic therapy treatment (\n* Patients taking drugs with photosensitivity as a side effect.\n* Persons with pacemakers or other implanted electronic medical device\n* Patients with viral conjunctivitis or any other infectious disease.\n* Patients with skin lesions on the neck or forehead\n* Patients at high risk of damage from optical radiation, such as aphakic patients, or patients with decreased sensitivity to light due to fundus disease.\n* Pregnant or lactating women\n* Participant unable to be followed throughout the study\n* Vulnerable people\n* Subjects with predisposition to closure of the iridocorneal angle",true,"18 Years",{"count":60,"type":21},1200,"INTERVENTIONAL",[63],"NA","Knowledge of the pathogenesis of ocular conditions, a leading cause of blindness, has benefited greatly from recent advances in ophthalmic imaging. However, current clinical imaging systems are limited in resolution, speed, or access to certain structures of the eye.\n\nThe use of a high-resolution imaging system improves the resolution of ophthalmoscopes by several orders of magnitude, allowing the visualization of many microstructures of the eye: photoreceptors, vessels, nerve bundles in the retina, cells and nerves in the cornea.\n\nThe use of a high-speed acquisition imaging system makes it possible to detect functional measurements such as the speed of blood flow. The combination of data from multiple imaging systems to obtain multimodal information is of great importance for improving the understanding of structural changes in the eye during a disease.\n\nThe purpose of this project is to observe structures that are not detectable with routinely used systems.",[66,67,68,69,70,71,72,73,74,75,76,27,77,78,79],"Retinitis Pigmentosa","Maculopathy, Age Related","Macular Dystrophy","Macular Edema","Retinal Detachment","Retinal Degeneration","Glaucoma","Vascular Inflammation","Hypertension","Stroke","Diabetes","Keratoconus","Dry Eye","Trauma","2025-11-17",{"date":82,"type":40},"2025-11-18",{"date":84,"type":40},"2019-07-03",{"date":86,"type":21},"2027-07",{"name":88,"class":89},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","OTHER",1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":57,"sex":16,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":90},"100324499","oct-in-diagnosis-of-irregular-corneas-100324499","NCT03504800","OCT in Diagnosis of Irregular Corneas","Optical Coherence Tomography-Aided Differential Diagnosis and Treatment of Irregular Corneas","Inclusion Criteria:\n\nGROUP A:\n\n* Keratoconus:\n\n  1. CDVA ≥ 20\u002F25 in the better eye; and both of the following in the worse eye\n  2. Topography characteristic of keratoconus or pellucid marginal degeneration\n* Contact lens-related corneal warpage:\n\n  1. Contact lens use; and\n  2. Topography irregularities\n* Dry eye:\n\n  1. Symptoms of dry eye documented by Ocular Surface Disease Index (OSDI) questionnaire score ≥ 30; and\n  2. Topography irregularities\n  3. Presence of punctate epithelial erosion on exam with surface staining\n  4. Aqueous deficiency or evaporative dry eye\n* Epithelial basement membrane dystrophy (EBMD):\n\n  1. Negative corneal fluorescein staining; and\n  2. Corneal opacities; and\n  3. Topography irregularities\n* Stromal addition or subtraction:\n\n  1. Scars; or\n  2. Salzmann's degeneration; or\n  3. Stromal dystrophies; or\n  4. Complication (visual complaints) after LASIK or photorefractive keratectomy (PRK)\n* Stromal distortion:\n\n  1. Radial keratectomy (RK); or\n  2. Corneal transplants.\n* Normal controls:\n\n  1. Healthy eyes with no previous eye procedures\u002Fsurgeries.\n\nGROUP B:\n\nParticipants will be selected from the keratoconus population in Group A based on topography findings.\n\nGROUP C:\n\nParticipants will be selected from the stromal addition\u002Fsubtraction and stromal distortion populations of Group A if they have vision primarily limited by scars, dystrophy, or high astigmatism that could benefit from PTK.\n\nExclusion Criteria (all groups):\n\n* Inability to give informed consent.\n* Inability to maintain fixation for OCT imaging.\n* Inability to commit to required study visits.\n* Eyes with concurrent cataract, retinal disease, glaucoma, or other eye conditions that may limit the visual outcome after surgery.\n* Previous corneal surgeries if considered as a keratoconus participant.\n* Pregnancy or breastfeeding.","14 Years","85 Years",{"count":101,"type":21},445,"This main goal of this study is to improve the detection, classification, monitoring, and treatment of irregular corneas due to keratoconus, warpage, dry eye, scar, stromal dystrophies, and other corneal conditions.\n\nThe primary goal will be achieved by using optical coherence tomography (OCT) to:\n\n1. Develop an OCT-based system to classify and evaluate corneal-shape irregularities.\n2. Develop OCT metrics for more sensitive detection of keratoconus progression.\n3. Develop OCT-and-topography guided phototherapeutic keratectomy (PTK) for irregular corneas.",[77,104,27],"Corneal Opacity",[106,77],"OCT","2025-09-05",{"date":109,"type":40},"2025-09-09",{"date":111,"type":40},"2018-05-01",{"date":113,"type":21},"2031-02-28",{"name":115,"class":89},"Oregon Health and Science University",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":61,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":90},"100580962","microsurgical-robot-assisted-corneal-transplant-100580962","NCT06844123","Microsurgical Robot-assisted Corneal Transplant","Graft Robot-Assisted Corneal Enhancement","GRACE","inclusion criteria :\n\n* Patients of legal age seen in a specialized ophthalmology consultation at the Reims University Hospital, and requiring transfixing keratoplasty.\n* Affiliated to a social security scheme\n* Agreeing to take part in the study (information and signature of consent form).\n\nexclusion criteria :\n\n* Patients protected by law\n* Patients with an ocular pathology other than their corneal pathology.\n* Mentally incapable of adhering to the principles of the study.","60 Years",{"count":126,"type":21},10,[63],"Full-thickness corneal grafting (transfixing keratoplasty) is a tissue graft described at the beginning of the 20th century, which has remained technically unchanged for several decades. Around 900 transfixing keratoplasties are performed every year in France. This microsurgical procedure is intended for patients with severe corneal pathology that seriously impairs visual function, and for whom no therapeutic alternative - optical devices, medication or other surgical procedure - exists.\n\nThe initial anatomical outcome of surgery depends on the accurate execution of the corneal sutures. Very recently, a robot with microsurgical capabilities was developed by the MMI company (Symani® surgical system, now available from the Reims University Hospital). This robot is equipped with forceps and a needle holder capable of handling fragile tissues and microsurgical needles with an amplitude of movement greater than that of the human hand. It is operated by a surgeon via a wireless controller and foot pedal. It could thus be used to perform the usual sutures of a transfixing keratoplasty.\n\nTo our knowledge, no study to date has evaluated the contribution of a microsurgical robot to transfixing keratoplasty in humans. The Symani® microsurgical robot recently received CE marking for microsurgery. The investigators were able to carry out a series of ex vivo keratoplasties using the robot to suture non-conforming human corneas (destined for destruction), thus proving the feasibility of the procedure.\n\nOn the basis of this proof of concept, our project aims to evaluate the performance of robot-assisted transfixing keratoplasty in patients requiring corneal transplantation. Robotic assistance for human eye surgery, particularly corneal transplants, has never been evaluated. The use of a robot to perform corneal sutures during transfixing keratoplasty could equal or even surpass the performance of this crucial surgical step, which is conventionally performed manually. Ultimately, visual results could be equivalent or even better than those obtained after conventional surgery. At the same time, the use of the robot will be evaluated in terms of surgical cost, in order to obtain a quantified financial evaluation of robot-assisted keratoplasty.",[27],"2025-06-25",{"date":132,"type":40},"2025-06-26",{"date":134,"type":40},"2025-06-06",{"date":136,"type":21},"2027-04",{"name":138,"class":89},"CHU de Reims",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":149,"conditions":150,"keywords":155,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":90},"100583856","fecd-trace-fuchs-endothelial-corneal-dystrophy-trajectory-and-correlation-with-genotype-in-the-united-kingdom-100583856","NCT06881771","FECD-TRACE: Fuchs' Endothelial Corneal Dystrophy TRAjectory and Correlation With Genotype in the United Kingdom","Investigating Genetic Causes and Molecular Mechanisms Responsible for Inherited Corneal Disease","FECD-TRACE","Inclusion Criteria:\n\n* Willing and able to provide informed consent for participation in the study\n* Willing to attend scheduled study visits and undergo a clinical examination\n* Willing to donate blood\u002Fsaliva samples\n* Fulfil the abovementioned cohort criteria\n\nExclusion Criteria:\n\n* Presence of a secondary cause for corneal endothelial dysfunction or oedema\n* Presence of clinically evident corneal oedema\n* History of concurrent corneal diseases\n* History of corneal surgeries, including corneal transplantation\n* Cognitive impairment or inability to provide informed consent for participation in the study",{"count":148,"type":21},500,"FECD-TRACE is an integral component of a large research program dedicated to Fuchs Endothelial Corneal Dystrophy (FECD) in the United Kingdom. This longitudinal, observational study aims to comprehensively characterize a cohort of younger research participants who have a genetic predisposition to developing FECD. By utilizing advanced anterior segment imaging techniques, the study will monitor these individuals over a span of several years, capturing phenotypic changes that reflect the progression of the disease. Concurrently, genetic biomarkers will be examined to establish correlations with the observed phenotypic changes. The primary objective of FECD-TRACE is to enhance our understanding of the intricate genetic mechanisms underlying FECD and establish connections between these genetic findings and clinical outcomes. Ultimately, this research strives to facilitate the development of personalized care approaches for individuals affected by FECD.",[151,152,153,154,27],"Fuchs Dystrophy","Fuchs' Endothelial Dystrophy","Fuchs' Endothelial Corneal Dystrophy of Bilateral Eyes","Corneal Dystrophy Fuchs",[156,157,158,159],"Fuchs' Corneal Endothelial Dystrophy","FECD","Corneal Dystrophies","Corneal Endothelial Dystrophy","2025-03-11",{"date":162,"type":40},"2025-03-18",{"date":164,"type":40},"2024-02-01",{"date":166,"type":21},"2027-02-01",{"name":168,"class":89},"University College, London"]